Biology of Bladder Cancer (R21 Clinical Trial Optional)

The National Institutes of Health (NIH) is inviting applications for the Biology of Bladder Cancer (R21 Clinical Trial Optional) Funding Opportunity Announcement (FOA), PAR-22-219. This grant supports exploratory and developmental research to advance understanding of bladder cancer biology, focusing on the mechanisms that drive initiation, progression, and malignancy. Bladder cancer is a major health concern globally due to its high incidence and recurrence, creating a significant medical and economic burden. This FOA aims to fill knowledge gaps in the molecular and cellular processes of bladder cancer and normal bladder function. Research projects using multidisciplinary approaches, clinical specimens, or investigations into both normal and pathological bladder processes are particularly encouraged. The program supports studies designed to generate preliminary data for future research and develop novel hypotheses in bladder cancer biology. Eligible applicants include state, county, and city governments; tribal governments and organizations; public and private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses; and for-profit organizations. Other eligible entities include Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, and foreign organizations. The R21 mechanism allows for up to $275,000 in total direct costs over a two-year project period, with no cost-sharing requirement. The current application deadline is September 7, 2025, though the next available submission window ends November 19, 2024. Interested applicants should carefully review NIH’s detailed guidelines for preparing and submitting applications.